One of these approaches is the development of therapeutic agents that exploit cell-surface EGFR as a decoy to direct the activity of key components of the adaptive immune system such as CD4+ T cells, B lymphocytes, and the cytotoxic CD8+ and γδ/αβ T-cell receptor positive (TCR+) T cells to EGFR-expressing cancer cells and to destroy them in a target-specific manner. This evidence concerns the gene EGFR and cancer.